February 12, 2020 – Genprex (NSDQ: GNPX) will be joining the 2020 Swiss Growth Forum Winter Edition as an official Presenting Company. They will be kickstarting the Forum with two private luncheons. We will begin the week on the 24th February at the Hotel Splendide Royal in Lugano and continue to Zunfthaus zur Zimmerleuten in Zurich on the 25th of February before continuing on to the SGF Winter Edition. We look forward to welcoming them on the week of 24th February in Lugano, Zurich and Geneva!

Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform. Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. The company’s lead product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC), has a multimodal mechanism of action whereby it has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells, re-establish pathways for apoptosis, or programmed cell death, in cancer cells, and modulate the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. In January 2020, the FDA granted Fast Track Designation for Oncoprex™ immunogene therapy for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso®)For more information, please visit the company’s web site at www.genprex.com or follow Genprex on TwitterFacebook and LinkedIn.

X